Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single-Center, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder

Next Previous
Trial Profile

An Open-Label, Single-Center, Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Autism Spectrum Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Autism spectrum disorder; Pervasive child development disorders
  • Focus Adverse reactions
  • Acronyms BRIGHT
  • Sponsors Zynerba Pharmaceuticals

Most Recent Events

  • 21 Oct 2021 According to a Zynerba Pharmaceuticals media release, data from the study will be presented at the 68th American Academy of Child & Adolescent Psychiatry (AACAP) Annual Meeting.
  • 21 Oct 2021 According to a Zynerba Pharmaceuticals media release, data from the study will be presented at the Society for Developmental & Behavioral Pediatrics (SDBP) Annual Meeting.
  • 08 Oct 2021 According to a Zynerba Pharmaceuticals media release, data from this trial presented at the 2021 American Academy of Pediatrics (AAP) National Conference & Exhibition, a copy of poster will be made available on the Zynerba corporate website

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top